Dyskinesia News and Research

RSS

MJFF awards $1.1M to six different projects for validating potential therapeutic targets for PD

The Michael J. Fox Foundation for Parkinson's Research today announced $1.1 million in total funding to six different projects aimed at validating potential therapeutic targets for Parkinson's disease.

9 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

In 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the structure of an ion channel his lab had been studying for five years.

24 Jun 2010

Despite FDA black box warning, prescription of Reglan for premature infants continue

Recently, researchers have observed a disturbing trend in neonatal units across the country: doctors prescribing Reglan -- also known by its generic name, metoclopramide -- to treat premature infants. This alarming development has raised serious concerns from many consumer safety advocates, particularly because the drug was never approved for use in infants.

4 May 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Whole genome sequencing of entire family beneficial

The Institute for Systems Biology (ISB) has analyzed the first whole genome sequences of a human family of four. The findings of a project funded through a partnership between ISB and the University of Luxembourg was published online today by Science on its Science Express website. It demonstrates the benefit of sequencing entire families, including lowering error rates, identifying rare genetic variants and identifying disease-linked genes.

11 Mar 2010

ISB uses Complete Genomics’ service to sequence genomes of four family members suffer from Miller syndrome

Complete Genomics Inc., a third-generation human genome sequencing company, today announced that the Institute for Systems Biology employed Complete Genomics’ human genome sequencing service to sequence a family quartet to determine the depth of genetic information possible in analyzing a full family’s sequence, and to verify the gene responsible for Miller syndrome, a rare craniofacial disorder.

11 Mar 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

Scott & White conducts DBS research for Parkinson's patients

At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.

27 Jan 2010

Projects investigating placebo effects in Parkinson's disease receive funds

The Michael J. Fox Foundation for Parkinson's Research announced funding for two projects investigating the placebo effect in Parkinson's disease.

30 Dec 2009

Grant of $1 million awarded to develop new treatments for dyskinesia

The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's disease.

22 Dec 2009

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

MONITORING FORCE files for Flibanserin orphan drug status designation with the EMEA

MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and preventing them from receiving optimal treatment for Parkinson's.

19 Nov 2009

Medicure announces results of operations for the three months ended August 31, 2009

Medicure Inc., today reported the results of operations for the three months ended August 31, 2009 (Q1 2009/10). All amounts cited below are in Canadian dollars unless otherwise noted.

15 Oct 2009

Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug

Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement with Santhera Pharmaceuticals (Switzerland) Ltd., a subsidiary of Santhera Pharmaceuticals Holding AG (SIX: SANN) to acquire the U.S. and Canadian rights to develop and commercialize Santhera’s JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson’s Disease (DPD). JP-1730/ fipamezole is a first-in-class compound that, in a recent Phase IIb study, displayed the potential to reduce levodopa-induced dyskinesia.

24 Aug 2009

Biovail acquires worldwide rights to Tetrabenazine

Biovail Corporation today announced a wholly owned subsidiary has entered into a definitive agreement to acquire worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman (tetrabenazine tablets), and the associated intellectual property rights held by Cambridge Laboratories (Ireland) Ltd and its affiliates.

18 May 2009

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Merck Serono announced today the initiation of the SETTLE study. This study will evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as add-on therapy to a stable dose of levodopa, in mid- to late-stage Parkinson's disease patients with motor fluctuations compared to placebo.

7 May 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009